Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell applies for TGA market approval for SmrtGraft™
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Remplir™ nerve repair study published in peer-reviewed clinical journal
Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical journal.
Orthocell receives $3.05m R&D tax incentive refund
Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Quarterly Report – Period To 31 March 2024
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Proactive Interview with Paul Anderson
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplir™.
Orthocell Successfully Completes Surgeries for Remplir™ US Market Authorisation
Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair study.
All surgical repairs of severed nerves were performed with no adverse events reported. This provides us with confidence that the final two stages, in which safety and effectiveness will be evaluated, will be consistent with the pilot study and positions the Company for US approval in 1Q CY25.
Top-line results from this study are expected in Q3 CY24, and Orthocell remains on schedule to submit its US 510(K) market authorisation application by the end of the year – with progression into sales soon thereafter.
Orthocell Managing Director, Paul Anderson, said:
“This study is an important next step in our international market access program with the potential to provide data demonstrating the impact and advantages of using Remplir over traditional nerve repair methods. We are excited to be at this important stage in the development of this product and remain committed to providing patients access to this life-changing treatment.”
The US addressable market in peripheral nerve repair is estimated to be worth more than US$1.1 billion annually, with an estimated 700,000 procedures where Remplir could be used, completed each year.
Proactive | Interview with CEO Paul Anderson
Orthocell CEO Paul Anderson spoke with Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
The West Australian | Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
Orthocell’s Company-led strategic placement has been reported in The West Australian newspaper, in an article by Senior Business Report Sean Smith titled “Chris Ellison, Rod Jones and the McCuskers jump into Orthocell”.
Orthocell Completes $3.5M Strategic Placement
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.